Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.36 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438007 | 0.85 | KIF11 (0.34) | MAP2K4ALDH1A1CYP1A2CYP2A6NOS1 | |
| SCHEMBL207457 | 0.74 | METAP2 (0.38) | MAP2K4ACHEALDH1A1KDM4EKEAP1 | |
| SCHEMBL2439787 | 0.74 | ALDH1A1 (0.47) | MAPK1ACHECA12CA9ALDH1A1 | |
| SCHEMBL28338500 | 0.72 | PRMT5 (0.39) | — | |
| SCHEMBL19356882 | 0.69 | IMPDH2 (0.43) | NOS1ITKL3MBTL1LOXL2 | |
| SCHEMBL2436272 | 0.69 | DAO (0.34) | — | |
| SCHEMBL2980594 | 0.67 | MAPT (0.51) | CA12CA9ALDH1A1MAPTNOS1 | |
| SCHEMBL14634225 | 0.67 | CCR1 (0.33) | CYP1A2NOS1 | |
| SCHEMBL2071518 | 0.65 | CA12 (0.38) | ACHECA12CA9ALDH1A1KDM4E | |
| SCHEMBL14485029 | 0.64 | GPR84 (0.42) | MAPK1CYP2A6ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | claimed |
| CN-117222650-A | Pyridine or pyrimido-ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| US-9238643-B2 | Amide compounds | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-19 | — | — | US | disclosed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | disclosed |
| US-20130245033-A1 | AMIDE COMPOUNDS | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2013-09-19 | — | — | US | disclosed |
| EP-2552211-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245033-A1 | AMIDE COMPOUNDS | AR, AVPR2, H1-0 | MAP2K4 4542/4885MAPK1 2719/4885MAPKAPK3 2519/4885 |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | MAP2K4 194/4885MAPK1 43/4885MAPKAPK3 90/4885 |
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | MAP2K4 234/4885MAPK1 99/4885MAPKAPK3 39/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | MAP2K4 4275/4885MAPK1 3698/4885MAPKAPK3 3485/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | MAP2K4 4478/4885MAPK1 3198/4885MAPKAPK3 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.